↓ Skip to main content

CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab

Overview of attention for article published in BMC Cancer, April 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
13 Mendeley